Flare Therapeutics

Executive Summary

Flare Therapeutics is a private biotechnology company pioneering a novel approach to target transcription factors, historically considered undruggable, using its proprietary platform that identifies critical 'switch sites' on these proteins. Founded in 2021 and headquartered in Cambridge, MA, the company has raised $123 million to develop precision small molecule medicines initially focused on oncology and neuroscience. Its lead program targets the estrogen receptor for hormone-driven cancers, aiming to overcome resistance to current therapies such as aromatase inhibitors and selective estrogen receptor degraders (SERDs). By leveraging structural insights and a rational drug design strategy, Flare aims to address a significant unmet need in breast cancer and other estrogen receptor-positive malignancies. The company's platform has the potential to be broadly applicable to other transcription factors in oncology and beyond, positioning it as a key player in the transcription factor targeting space.

Upcoming Catalysts (preview)

• Q4 2026IND Submission for Lead Estrogen Receptor Program70% success
• H1 2027Platform Partnership or Licensing Deal for Neuroscience Program50% success
• Q3 2026Presentation of Preclinical Data at Major Medical Conference90% success